Search for a doctor

Laurence J. Miller, M.D.

  1. Gastroenterologist
  2. Internist
Request an Appointment

Publications

  1. Ardecky R, Dengler DG, Harikumar KG, Abelman MM, Zou J, Kramer BA, Ganji SR, Olson S, Ly A, Puvvula N, Ma CT, Ramachandra R, Sergienko EA, Miller LJ. Structure-activity relationships of thiadiazole agonists of the human secretin receptor. SLAS Discov. 2024 Sep; 29 (6):100176 Epub 2024 Aug 08
    View PubMed
  2. Stoneman MR, Yokoi K, Biener G, Killeen TD, Adhikari DP, Rahman S, Harikumar KG, Miller LJ, Raicu V. Mechanistic insights from the atomic-level quaternary structure of short-lived GPCR oligomers in live cells. Res Sq. 2024 Jul 19 Epub 2024 July 19
    View PubMed
  3. Harikumar KG, Zhao P, Cary BP, Xu X, Desai AJ, Dong M, Mobbs JI, Toufaily C, Furness SGB, Christopoulos A, Belousoff MJ, Wootten D, Sexton PM, Miller LJ. Cholesterol-dependent dynamic changes in the conformation of the type 1 cholecystokinin receptor affect ligand binding and G protein coupling. PLoS Biol. 2024 Jul; 22 (7):e3002673 Epub 2024 July 31
    View PubMed
  4. Harikumar KG, Piper SJ, Christopoulos A, Wootten D, Sexton PM, Miller LJ. Impact of secretin receptor homo-dimerization on natural ligand binding. Nat Commun. 2024 May 23; 15 (1):4390
    View PubMed
  5. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA, Abbracchio MP, Abraham G, Agoulnik A, Alexander W, Al-Hosaini K, Back M, Baker JG, Barnes NM, Bathgate R, Beaulieu JM, Beck-Sickinger AG, Behrens M, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C, Brauner-Osborne H, Burnstock G, Calo G, Castano JP, Catt KJ, Ceruti S, Chazot P, Chiang N, Chini B, Chun J, Cianciulli A, Civelli O, Clapp LH, Couture R, Cox HM, Csaba Z, Dahlgren C, Dent G, Douglas SD, Dournaud P, Eguchi S, Escher E, Filardo EJ, Fong T, Fumagalli M, Gainetdinov RR, Garelja ML, de Gasparo M, Gerard C, Gershengorn M, Gobeil F, Goodfriend TL, Goudet C, Gratz L, Gregory KJ, Gundlach AL, Hamann J, Hanson J, Hauger RL, Hay DL, Heinemann A, Herr D, Hollenberg MD, Holliday ND, Horiuchi M, Hoyer D, Hunyady L, Husain A, IJzerman AP, Inagami T, Jacobson KA, Jensen RT, Jockers R, Jonnalagadda D, Karnik S, Kaupmann K, Kemp J, Kennedy C, Kihara Y, Kitazawa T, Kozielewicz P, Kreienkamp HJ, Kukkonen JP, Langenhan T, Larhammar D, Leach K, Lecca D, Lee JD, Leeman SE, Leprince J, Li XX, Lolait SJ, Lupp A, Macrae R, Maguire J, Malfacini D, Mazella J, McArdle CA, Melmed S, Michel MC, Miller LJ, Mitolo V, Mouillac B, Muller CE, Murphy PM, Nahon JL, Ngo T, Norel X, Nyimanu D, O'Carroll AM, Offermanns S, Panaro MA, Parmentier M, Pertwee RG, Pin JP, Prossnitz ER, Quinn M, Ramachandran R, Ray M, Reinscheid RK, Rondard P, Rovati GE, Ruzza C, Sanger GJ, Schoneberg T, Schulte G, Schulz S, Segaloff DL, Serhan CN, Singh KD, Smith CM, Stoddart LA, Sugimoto Y, Summers R, Tan VP, Thal D, Thomas WW, Timmermans PBMWM, Tirupula K, Toll L, Tulipano G, Unal H, Unger T, Valant C, Vanderheyden P, Vaudry D, Vaudry H, Vilardaga JP, Walker CS, Wang JM, Ward DT, Wester HJ, Willars GB, Williams TL, Woodruff TM, Yao C, Ye RD. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. Br J Pharmacol. 2023 Oct; 180 Suppl 2:S23-S144
    View PubMed
  6. Dengler DG, Harikumar KG, Yen A, Sergienko EA, Miller LJ. Mechanism of Action and Structure-Activity Relationships of Tetracyclic Small Molecules Acting as Universal Positive Allosteric Modulators of the Cholecystokinin Receptor. Membranes (Basel). 2023 Jan 24; 13 (2)
    View PubMed
  7. Dengler DG, Sun Q, Harikumar KG, Miller LJ, Sergienko EA. Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity. SLAS Discov. 2022 Oct; 27 (7):384-394 Epub 2022 July 16
    View PubMed
  8. Lu J, Piper SJ, Zhao P, Miller LJ, Wootten D, Sexton PM. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors. Int J Mol Sci. 2022 Jul 22; 23 (15) Epub 2022 July 22
    View PubMed
  9. Milburn JE, Harikumar KG, Piper SJ, Raval S, Christopoulos A, Wootten D, Sexton PM, Miller LJ. Secretin Amino-Terminal Structure-Activity Relationships and Complementary Mutagenesis at the Site of Docking to the Secretin Receptor. Mol Pharmacol. 2022 Jun; 101 (6):400-407 Epub 2022 Mar 29
    View PubMed
  10. Alexander SP, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Abbracchio MP, Alexander W, Al-Hosaini K, Back M, Barnes NM, Bathgate R, Beaulieu JM, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C, Brauner-Osborne H, Burnstock G, Calo G, Castano JP, Catt KJ, Ceruti S, Chazot P, Chiang N, Chini B, Chun J, Cianciulli A, Civelli O, Clapp LH, Couture R, Csaba Z, Dahlgren C, Dent G, Singh KD, Douglas SD, Dournaud P, Eguchi S, Escher E, Filardo EJ, Fong T, Fumagalli M, Gainetdinov RR, Gasparo M, Gerard C, Gershengorn M, Gobeil F, Goodfriend TL, Goudet C, Gregory KJ, Gundlach AL, Hamann J, Hanson J, Hauger RL, Hay DL, Heinemann A, Hollenberg MD, Holliday ND, Horiuchi M, Hoyer D, Hunyady L, Husain A, IJzerman AP, Inagami T, Jacobson KA, Jensen RT, Jockers R, Jonnalagadda D, Karnik S, Kaupmann K, Kemp J, Kennedy C, Kihara Y, Kitazawa T, Kozielewicz P, Kreienkamp HJ, Kukkonen JP, Langenhan T, Leach K, Lecca D, Lee JD, Leeman SE, Leprince J, Li XX, Williams TL, Lolait SJ, Lupp A, Macrae R, Maguire J, Mazella J, McArdle CA, Melmed S, Michel MC, Miller LJ, Mitolo V, Mouillac B, Muller CE, Murphy P, Nahon JL, Ngo T, Norel X, Nyimanu D, O'Carroll AM, Offermanns S, Panaro MA, Parmentier M, Pertwee RG, Pin JP, Prossnitz ER, Quinn M, Ramachandran R, Ray M, Reinscheid RK, Rondard P, Rovati GE, Ruzza C, Sanger GJ, Schoneberg T, Schulte G, Schulz S, Segaloff DL, Serhan CN, Stoddart LA, Sugimoto Y, Summers R, Tan VP, Thal D, Thomas WW, Timmermans PBMWM, Tirupula K, Tulipano G, Unal H, Unger T, Valant C, Vanderheyden P, Vaudry D, Vaudry H, Vilardaga JP, Walker CS, Wang JM, Ward DT, Wester HJ, Willars GB, Woodruff TM, Yao C, Ye RD. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. Br J Pharmacol. 2021 Oct; 178 Suppl 1:S27-S156
    View PubMed
  11. Geiger J, Sexton R, Al-Sahouri Z, Lee MY, Chun E, Harikumar KG, Miller LJ, Beckstein O, Liu W. Evidence that specific interactions play a role in the cholesterol sensitivity of G protein-coupled receptors. Biochim Biophys Acta Biomembr. 2021 Sep 1; 1863 (9):183557 Epub 2021 Jan 11
    View PubMed
  12. Yan Y, Mukherjee S, Harikumar KG, Strutzenberg TS, Zhou XE, Suino-Powell K, Xu TH, Sheldon RD, Lamp J, Brunzelle JS, Radziwon K, Ellis A, Novick SJ, Vega IE, Jones RG, Miller LJ, Xu HE, Griffin PR, Kossiakoff AA, Melcher K. Structure of an AMPK complex in an inactive, ATP-bound state. Science. 2021 Jul 23; 373 (6553):413-419
    View PubMed
  13. Mobbs JI, Belousoff MJ, Harikumar KG, Piper SJ, Xu X, Furness SGB, Venugopal H, Christopoulos A, Danev R, Wootten D, Thal DM, Miller LJ, Sexton PM. Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. PLoS Biol. 2021 Jun; 19 (6):e3001295 Epub 2021 June 04
    View PubMed
  14. Asher WB, Geggier P, Holsey MD, Gilmore GT, Pati AK, Meszaros J, Terry DS, Mathiasen S, Kaliszewski MJ, McCauley MD, Govindaraju A, Zhou Z, Harikumar KG, Jaqaman K, Miller LJ, Smith AW, Blanchard SC, Javitch JA. Single-molecule FRET imaging of GPCR dimers in living cells. Nat Methods. 2021 Apr; 18 (4):397-405 Epub 2021 Mar 08
    View PubMed
  15. Dengler DG, Harikumar KG, Pollari S, Sun Q, Brown BT, Shinoki-Iwaya A, Ardecky R, Miller LJ, Sergienko EA. Discovery of small molecule positive allosteric modulators of the secretin receptor. Biochem Pharmacol. 2021 Mar; 185:114451 Epub 2021 Feb 03
    View PubMed
  16. Harikumar KG, Coudrat T, Desai AJ, Dong M, Dengler DG, Furness SGB, Christopoulos A, Wootten D, Sergienko EA, Sexton PM, Miller LJ. Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol. Front Endocrinol (Lausanne). 2021; 12:789957 Epub 2021 Dec 07
    View PubMed
  17. Miller LJ, Harikumar KG, Wootten D, Sexton PM. Roles of Cholecystokinin in the Nutritional Continuum. Physiology and Potential Therapeutics. Front Endocrinol (Lausanne). 2021; 12:684656 Epub 2021 June 02
    View PubMed
  18. Dengler DG, Sun Q, Holleran J, Pollari S, Beutel J, Brown BT, Shinoki Iwaya A, Ardecky R, Harikumar KG, Miller LJ, Sergienko EA. Development of a Testing Funnel for Identification of Small-Molecule Modulators Targeting Secretin Receptors. SLAS Discov. 2021 Jan; 26 (1):1-16 Epub 2020 Aug 04
    View PubMed
  19. Zhang X, Belousoff MJ, Zhao P, Kooistra AJ, Truong TT, Ang SY, Underwood CR, Egebjerg T, Senel P, Stewart GD, Liang YL, Glukhova A, Venugopal H, Christopoulos A, Furness SGB, Miller LJ, Reedtz-Runge S, Langmead CJ, Gloriam DE, Danev R, Sexton PM, Wootten D. Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Mol Cell. 2020 Nov 5; 80 (3):485-500.e7 Epub 2020 Oct 06
    View PubMed
  20. Dong M, Deganutti G, Piper SJ, Liang YL, Khoshouei M, Belousoff MJ, Harikumar KG, Reynolds CA, Glukhova A, Furness SGB, Christopoulos A, Danev R, Wootten D, Sexton PM, Miller LJ. Structure and dynamics of the active Gs-coupled human secretin receptor. Nat Commun. 2020 Aug 18; 11 (1):4137
    View PubMed
  21. Dong M, Harikumar KG, Raval SR, Milburn JE, Clark C, Alcala-Torano R, Mobarec JC, Reynolds CA, Ghirlanda G, Christopoulos A, Wootten D, Sexton PM, Miller LJ. Rational development of a high-affinity secretin receptor antagonist. Biochem Pharmacol. 2020 Jul; 177:113929 Epub 2020 Mar 23
    View PubMed
  22. Liang YL, Belousoff MJ, Fletcher MM, Zhang X, Khoshouei M, Deganutti G, Koole C, Furness SGB, Miller LJ, Hay DL, Christopoulos A, Reynolds CA, Danev R, Wootten D, Sexton PM. Structure and Dynamics of Adrenomedullin Receptors AM(1) and AM(2) Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins. ACS Pharmacol Transl Sci. 2020 Apr 10; 3 (2):263-284 Epub 2020 Mar 20
    View PubMed
  23. Brandler J, Miller LJ, Wang XJ, Burton D, Busciglio I, Arndt K, Harmsen WS, Camilleri M. Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial. Am J Physiol Gastrointest Liver Physiol. 2020 Apr 1; 318 (4):G635-G645 Epub 2020 Feb 10
    View PubMed
  24. Miller LJ, Harikumar KG, Desai AJ, Siddiki H, Nguyen BD. Kinetics of Gallbladder Emptying During Cholecystokinin Cholescintigraphy as an Indicator of In Vivo Hormonal Sensitivity. J Nucl Med Technol. 2020 Mar; 48 (1):40-45 Epub 2019 Oct 11
    View PubMed
  25. Wootten D, Miller LJ. Structural Basis for Allosteric Modulation of Class B G Protein-Coupled Receptors. Annu Rev Pharmacol Toxicol. 2020 Jan 6; 60:89-107 Epub 2019 Aug 27
    View PubMed
  26. Zhao P, Liang YL, Belousoff MJ, Deganutti G, Fletcher MM, Willard FS, Bell MG, Christe ME, Sloop KW, Inoue A, Truong TT, Clydesdale L, Furness SGB, Christopoulos A, Wang MW, Miller LJ, Reynolds CA, Danev R, Sexton PM, Wootten D. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan; 577 (7790):432-436 Epub 2020 Jan 08
    View PubMed
  27. Desai AJ, Mechin I, Nagarajan K, Valant C, Wootten D, Lam PCH, Orry A, Abagyan R, Nair A, Sexton PM, Christopoulos A, Miller LJ. Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor. Mol Pharmacol. 2019 Mar; 95 (3):245-259 Epub 2018 Dec 27
    View PubMed
  28. Dal Maso E, Glukhova A, Zhu Y, Garcia-Nafria J, Tate CG, Atanasio S, Reynolds CA, Ramirez-Aportela E, Carazo JM, Hick CA, Furness SGB, Hay DL, Liang YL, Miller LJ, Christopoulos A, Wang MW, Wootten D, Sexton PM. The Molecular Control of Calcitonin Receptor Signaling. ACS Pharmacol Transl Sci. 2019 Feb 8; 2 (1):31-51 Epub 2019 Jan 11
    View PubMed
  29. Tuzmen S, Hostetter G, Watanabe A, Ekmekci C, Carrigan PE, Shechter I, Kallioniemi O, Miller LJ, Mousses S. Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer. Per Med. 2019 Jan; 16 (1):51-65 Epub 2018 Nov 23
    View PubMed
  30. Desai AJ, Miller LJ. Changes in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function. Br J Pharmacol. 2018 Nov; 175 (21):4009-4025 Epub 2017 Aug 03
    View PubMed
  31. Liang YL, Khoshouei M, Deganutti G, Glukhova A, Koole C, Peat TS, Radjainia M, Plitzko JM, Baumeister W, Miller LJ, Hay DL, Christopoulos A, Reynolds CA, Wootten D, Sexton PM. Cryo-EM structure of the active, G(s)-protein complexed, human CGRP receptor. Nature. 2018 Sep; 561 (7724):492-497 Epub 2018 Sept 12
    View PubMed
  32. Yang S, Wu Y, Xu TH, de Waal PW, He Y, Pu M, Chen Y, DeBruine ZJ, Zhang B, Zaidi SA, Popov P, Guo Y, Han GW, Lu Y, Suino-Powell K, Dong S, Harikumar KG, Miller LJ, Katritch V, Xu HE, Shui W, Stevens RC, Melcher K, Zhao S, Xu F. Crystal structure of the Frizzled 4 receptor in a ligand-free state. Nature. 2018 Aug; 560 (7720):666-670 Epub 2018 Aug 22
    View PubMed
  33. Liang YL, Khoshouei M, Glukhova A, Furness SGB, Zhao P, Clydesdale L, Koole C, Truong TT, Thal DM, Lei S, Radjainia M, Danev R, Baumeister W, Wang MW, Miller LJ, Christopoulos A, Sexton PM, Wootten D. Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. Nature. 2018 Mar 1; 555 (7694):121-125 Epub 2018 Feb 21
    View PubMed
  34. Pannala R, Baldwin B, Aluru V, Grys TE, Holmes J, Miller LJ, Harrison ME, Nguyen CC, Tenover FC, Persing D, Faigel DO. Prospective study of the feasibility of point-of-care testing strategy for carbapenem-resistant organism detection. Endosc Int Open. 2018 Jan; 6 (1):E58-E63 Epub 2018 Jan 12
    View PubMed
  35. Xu TH, Yan Y, Harikumar KG, Miller LJ, Melcher K, Xu HE. gamma-Secretase Epsilon-cleavage Assay. Bio Protoc. 2017 Nov 20; 7 (22)
    View PubMed
  36. Yan Y, Xu TH, Harikumar KG, Miller LJ, Melcher K, Xu HE. Detection of Membrane Protein Interactions by Cell-based Tango Assays. Bio Protoc. 2017 Nov 20; 7 (22)
    View PubMed
  37. Harikumar KG, Yan Y, Xu TH, Melcher K, Xu HE, Miller LJ. Bioluminescence Resonance Energy Transfer (BRET) Assay for Determination of Molecular Interactions in Living Cells. Bio Protoc. 2017 Nov 20; 7 (22)
    View PubMed
  38. Xu TH, Yan Y, Harikumar KG, Miller LJ, Melcher K, Xu HE. Streptavidin Bead Pulldown Assay to Determine Protein Homooligomerization. Bio Protoc. 2017 Nov 20; 7 (22)
    View PubMed
  39. Ramil CP, Dong M, An P, Lewandowski TM, Yu Z, Miller LJ, Lin Q. Spirohexene-Tetrazine Ligation Enables Bioorthogonal Labeling of Class B G Protein-Coupled Receptors in Live Cells. J Am Chem Soc. 2017 Sep 27; 139 (38):13376-13386 Epub 2017 Sept 15
    View PubMed
  40. Yan Y, Xu TH, Harikumar KG, Miller LJ, Melcher K, Xu HE. Dimerization of the transmembrane domain of amyloid precursor protein is determined by residues around the gamma-secretase cleavage sites. J Biol Chem. 2017 Sep 22; 292 (38):15826-15837 Epub 2017 Aug 08
    View PubMed
  41. Desai AJ, Dong M, Langlais BT, Dueck AC, Miller LJ. Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype. Am J Clin Nutr. 2017 Aug; 106 (2):447-456 Epub 2017 June 07
    View PubMed
  42. Liang YL, Khoshouei M, Radjainia M, Zhang Y, Glukhova A, Tarrasch J, Thal DM, Furness SGB, Christopoulos G, Coudrat T, Danev R, Baumeister W, Miller LJ, Christopoulos A, Kobilka BK, Wootten D, Skiniotis G, Sexton PM. Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature. 2017 Jun 1; 546 (7656):118-123 Epub 2017 Apr 24
    View PubMed
  43. Harikumar KG, Lau S, Sexton PM, Wootten D, Miller LJ. Coexpressed Class B G Protein-Coupled Secretin and GLP-1 Receptors Self- and Cross-Associate: Impact on Pancreatic Islets. Endocrinology. 2017 Jun 1; 158 (6):1685-1700
    View PubMed
  44. Ward RJ, Pediani JD, Harikumar KG, Miller LJ, Milligan G. Spatial intensity distribution analysis quantifies the extent and regulation of homodimerization of the secretin receptor. Biochem J. 2017 May 24; 474 (11):1879-1895
    View PubMed
  45. DeBruine ZJ, Ke J, Harikumar KG, Gu X, Borowsky P, Williams BO, Xu W, Miller LJ, Xu HE, Melcher K. Wnt5a promotes Frizzled-4 signalosome assembly by stabilizing cysteine-rich domain dimerization. Genes Dev. 2017 May 1; 31 (9):916-926 Epub 2017 May 25
    View PubMed
  46. Wootten D, Miller LJ, Koole C, Christopoulos A, Sexton PM. Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. Chem Rev. 2017 Jan 11; 117 (1):111-138 Epub 2016 Apr 04
    View PubMed
  47. Desai AJ, Dong M, Miller LJ. Beneficial effects of beta-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol. Clin Nutr. 2016 Dec; 35 (6):1374-1379 Epub 2016 Mar 15
    View PubMed
  48. Desai AJ, Dong M, Harikumar KG, Miller LJ. Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor. Int J Obes Suppl. 2016 Dec; 6 (Suppl 1):S22-S27 Epub 2016 Nov 16
    View PubMed
  49. Wootten D, Reynolds CA, Smith KJ, Mobarec JC, Furness SG, Miller LJ, Christopoulos A, Sexton PM. Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor. Biochem Pharmacol. 2016 Oct 15; 118:68-87 Epub 2016 Aug 26
    View PubMed
  50. Graaf Cd, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, Ahn JM, Liao J, Fletcher MM, Yang D, Brown AJ, Zhou C, Deng J, Wang MW. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev. 2016 Oct; 68 (4):954-1013
    View PubMed
  51. Miller LJ, Desai AJ. Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target. Trends Endocrinol Metab. 2016 Sep; 27 (9):609-619 Epub 2016 May 04
    View PubMed
  52. Harikumar KG, Augustine ML, Lee LT, Chow BK, Miller LJ. Structure and Function of Cross-class Complexes of G Protein-coupled Secretin and Angiotensin 1a Receptors. J Biol Chem. 2016 Aug 12; 291 (33):17332-44 Epub 2016 June 21
    View PubMed
  53. Wootten D, Reynolds CA, Smith KJ, Mobarec JC, Koole C, Savage EE, Pabreja K, Simms J, Sridhar R, Furness SGB, Liu M, Thompson PE, Miller LJ, Christopoulos A, Sexton PM. The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism. Cell. 2016 Jun 16; 165 (7):1632-1643
    View PubMed
  54. Dong M, Lam PC, Orry A, Sexton PM, Christopoulos A, Abagyan R, Miller LJ. Use of Cysteine Trapping to Map Spatial Approximations between Residues Contributing to the Helix N-capping Motif of Secretin and Distinct Residues within Each of the Extracellular Loops of Its Receptor. J Biol Chem. 2016 Mar 4; 291 (10):5172-84 Epub 2016 Jan 06
    View PubMed
  55. Wootten D, Reynolds CA, Koole C, Smith KJ, Mobarec JC, Simms J, Quon T, Coudrat T, Furness SG, Miller LJ, Christopoulos A, Sexton PM. A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures. Mol Pharmacol. 2016 Mar; 89 (3):335-47 Epub 2015 Dec 23
    View PubMed
  56. Ng HK, Harikumar KG, Miller LJ, Chow BK. Signaling Modification by GPCR Heteromer and Its Implication on X-Linked Nephrogenic Diabetes Insipidus. PLoS One. 2016; 11 (9):e0163086 Epub 2016 Sept 20
    View PubMed
  57. Desai AJ, Lam PC, Orry A, Abagyan R, Christopoulos A, Sexton PM, Miller LJ. Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. J Med Chem. 2015 Dec 24; 58 (24):9562-77 Epub 2015 Dec 10
    View PubMed
  58. Desai AJ, Dong M, Harikumar KG, Miller LJ. Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function. Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1; 309 (5):G377-86 Epub 2015 July 02
    View PubMed
  59. Desai AJ, Henke BR, Miller LJ. Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity. Bioorg Med Chem Lett. 2015 May 1; 25 (9):1849-55 Epub 2015 Mar 24
    View PubMed
  60. Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery. J Pharmacol Exp Ther. 2015 Apr; 353: (1)52-63.
    View PubMed
  61. Dong M, Vattelana AM, Lam PC, Orry AJ, Abagyan R, Christopoulos A, Sexton PM, Haines DR, Miller LJ. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding. Mol Pharmacol. 2015 Jan; 87 (1):130-40 Epub 2014 Oct 15
    View PubMed
  62. Harikumar KG, Miller LJ. Use of Fluorescence Indicators in Receptor Ligands. Methods Mol Biol. 2015; 1335:115-30.
    View PubMed
  63. Miller LJ, Sexton PM, Dong M, Harikumar KG. The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus. Int J Obes Suppl. 2014 Jul; 4 (Suppl 1):S9-S13 Epub 2014 July 08
    View PubMed
  64. Desai AJ, Harikumar KG, Miller LJ. A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment. J Biol Chem. 2014 Jun 27; 289 (26):18314-26 Epub 2014 May 13
    View PubMed
  65. Lee LT, Ng SY, Chu JY, Sekar R, Harikumar KG, Miller LJ, Chow BK. Transmembrane peptides as unique tools to demonstrate the in vivo action of a cross-class GPCR heterocomplex. FASEB J. 2014 Jun; 28 (6):2632-44 Epub 2014 Mar 05
    View PubMed
  66. Dong M, Koole C, Wootten D, Sexton PM, Miller LJ. Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs. Br J Pharmacol. 2014 Mar; 171 (5):1085-101
    View PubMed
  67. Ke J, Harikumar KG, Erice C, Chen C, Gu X, Wang L, Parker N, Cheng Z, Xu W, Williams BO, Melcher K, Miller LJ, Xu HE. Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5/6 complex. Genes Dev. 2013 Nov 1; 27(21):2305-19.
    View PubMed
  68. Dong M, Miller LJ. Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling. Peptides. 2013 Aug; 46:143-9 Epub 2013 June 14
    View PubMed
  69. Koole C, Savage EE, Christopoulos A, Miller LJ, Sexton PM, Wootten D. Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery. Mol Endocrinol. 2013 Aug; 27(8):1234-44. Epub 2013 Jul 17.
    View PubMed
  70. Harikumar KG, Cawston EE, Lam PCH, Patil A, Orry A, Henke BR, Abagyan R, Christopoulos A, Sexton PM, Miller LJ. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor. J Biol Chem. 2013 Jul 19; 288 (29):21082-21095 Epub 2013 June 10
    View PubMed
  71. Lomberk G, Grzenda A, Mathison A, Escande C, Zhang JS, Calvo E, Miller LJ, Iovanna J, Chini EN, Fernandez-Zapico ME, Urrutia R. Kruppel-like factor 11 regulates the expression of metabolic genes via an evolutionarily conserved protein interaction domain functionally disrupted in maturity onset diabetes of the young. J Biol Chem. 2013 Jun 14; 288 (24):17745-58 Epub 2013 Apr 15
    View PubMed
  72. Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci U S A. 2013 Mar 26; 110(13):5211-6. Epub 2013 Mar 11.
    View PubMed
  73. Harikumar KG, Potter RM, Patil A, Echeveste V, Miller LJ. Membrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol. Lipids. 2013 Mar; 48 (3):231-44 Epub 2013 Jan 11
    View PubMed
  74. Miller LJ, Dong M. The orthosteric agonist-binding pocket in the prototypic class B G-protein-coupled secretin receptor. Biochem Soc Trans. 2013 Feb 1; 41(1):154-8.
    View PubMed
  75. Koole C, Pabreja K, Savage EE, Wootten D, Furness SG, Miller LJ, Christopoulos A, Sexton PM. Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. Biochem Soc Trans. 2013 Feb 1; 41(1):172-9.
    View PubMed
  76. Qi T, Dong M, Watkins HA, Wootten D, Miller LJ, Hay DL. Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Delta(1-47)hCT((a)) function. Br J Pharmacol. 2013 Feb; 168(3):644-57.
    View PubMed
  77. Dong M, Pinon DI, Miller LJ. Insights into the impact of phenolic residue incorporation at each position along secretin for receptor binding and biological activity. Regul Pept. 2013 Jan 10; 180:5-11 Epub 2012 Nov 08
    View PubMed
  78. Miller LJ. Molecular basis of peptide activation of the GLP-1 receptor. Mol Metab. 2013; 2 (2):60-1 Epub 2013 Mar 06
    View PubMed
  79. Dong M, Xu X, Ball AM, Makhoul JA, Lam PC, Pinon DI, Orry A, Sexton PM, Abagyan R, Miller LJ. Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB J. 2012 Dec; 26 (12):5092-105 Epub 2012 Sept 10
    View PubMed
  80. Harikumar KG, Wootten D, Pinon DI, Koole C, Ball AM, Furness SG, Graham B, Dong M, Christopoulos A, Miller LJ, Sexton PM. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc Natl Acad Sci U S A. 2012 Nov 6; 109 (45):18607-12 Epub 2012 Oct 22
    View PubMed
  81. Te JA, Dong M, Miller LJ, Bordner AJ. Predicting the effects of amino acid replacements in peptide hormones on their binding affinities for class B GPCRs and application to the design of secretin receptor antagonists. J Comput Aided Mol Des. 2012 Jul; 26 (7):835-45 Epub 2012 May 11
    View PubMed
  82. Cawston EE, Lam PC, Harikumar KG, Dong M, Ball AM, Augustine ML, Akgun E, Portoghese PS, Orry A, Abagyan R, Sexton PM, Miller LJ. Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor. J Biol Chem. 2012 May 25; 287 (22):18618-35 Epub 2012 Mar 30
    View PubMed
  83. Miller LJ, Dong M, Harikumar KG. Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor. Br J Pharmacol. 2012 May; 166 (1):18-26
    View PubMed
  84. Garcia GL, Dong M, Miller LJ. Differential determinants for coupling of distinct G proteins with the class B secretin receptor. Am J Physiol Cell Physiol. 2012 Apr 15; 302 (8):C1202-12 Epub 2012 Jan 25
    View PubMed
  85. Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J Biol Chem. 2012 Feb 3; 287(6):3642-58. Epub 2011 Dec 06.
    View PubMed
  86. Koole C, Wootten D, Simms J, Savage EE, Miller LJ, Christopoulos A, Sexton PM. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J Biol Chem. 2012 Feb 3; 287(6):3659-73. Epub 2011 Dec 06.
    View PubMed
  87. Cawston EE, Harikumar KG, Miller LJ. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity. Am J Physiol Cell Physiol. 2012 Feb 1; 302 (3):C615-27 Epub 2011 Nov 02
    View PubMed
  88. Desai AJ, Miller LJ. Sensitivity of cholecystokinin receptors to membrane cholesterol content. Front Endocrinol (Lausanne). 2012; 3:123 Epub 2012 Oct 18
    View PubMed
  89. Potter RM, Harikumar KG, Wu SV, Miller LJ. Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol. J Lipid Res. 2012 Jan; 53 (1):137-48 Epub 2011 Oct 21
    View PubMed
  90. Ke J, Zhang C, Harikumar KG, Zylstra-Diegel CR, Wang L, Mowry LE, Miller LJ, Williams BO, Xu HE. Modulation of beta-catenin signaling by glucagon receptor activation. PLoS One. 2012; 7(3):e33676. Epub 2012 Mar 16.
    View PubMed
  91. Dong M, Pinon DI, Miller LJ. Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket. Bioorg Med Chem Lett. 2012 Jan 1; 22 (1):638-41 Epub 2011 Oct 25
    View PubMed
  92. Katchman BA, Antwi K, Hostetter G, Demeure MJ, Watanabe A, Decker GA, Miller LJ, Von Hoff, Lake DF. Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. Mol Cancer Res. 2011 Dec; 9(12):1621-31. Epub 2011 Oct 11.
    View PubMed
  93. Dong M, Te JA, Xu X, Wang J, Pinon DI, Storjohann L, Bordner AJ, Miller LJ. Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist. Biochemistry. 2011 Sep 27; 50 (38):8181-92 Epub 2011 Aug 30
    View PubMed
  94. Koole C, Wootten D, Simms J, Valant C, Miller LJ, Christopoulos A, Sexton PM. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol. 2011 Sep; 80(3):486-97. Epub 2011 May 26.
    View PubMed
  95. Harikumar KG, Cawston EE, Miller LJ. Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor. Assay Drug Dev Technol. 2011 Aug; 9 (4):394-402 Epub 2011 Mar 11
    View PubMed
  96. Dong M, Lam PC, Pinon DI, Hosohata K, Orry A, Sexton PM, Abagyan R, Miller LJ. Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. J Biol Chem. 2011 Jul 8; 286 (27):23888-99 Epub 2011 May 12
    View PubMed
  97. Miller LJ, Chen Q, Lam PC, Pinon DI, Sexton PM, Abagyan R, Dong M. Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem. 2011 May 6; 286 (18):15895-907 Epub 2011 Mar 16
    View PubMed
  98. Dong M, Le A, Te JA, Pinon DI, Bordner AJ, Miller LJ. Importance of each residue within secretin for receptor binding and biological activity. Biochemistry. 2011 Apr 12; 50 (14):2983-93 Epub 2011 Mar 21
    View PubMed
  99. Carrigan PE, Bingham JL, Srinvasan S, Brentnall TA, Miller LJ. Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer. Pancreas. 2011 Mar; 40 (2):281-8
    View PubMed
  100. Fry BG, Winter K, Norman JA, Roelants K, Nabuurs RJ, van Osch MJ, Teeuwisse WM, van der Weerd L, McNaughtan JE, Kwok HF, Scheib H, Greisman L, Kochva E, Miller LJ, Gao F, Karas J, Scanlon D, Lin F, Kuruppu S, Shaw C, Wong L, Hodgson WC. Functional and structural diversification of the Anguimorpha lizard venom system. Mol Cell Proteomics. 2010 Nov; 9(11):2369-90. Epub 2010 Jul 14.
    View PubMed
  101. Dong M, Pinon DI, Bordner AJ, Miller LJ. Elucidation of the active conformation of the amino terminus of receptor-bound secretin using intramolecular disulfide bond constraints. Bioorg Med Chem Lett. 2010 Oct 15; 20 (20):6040-4 Epub 2010 Aug 15
    View PubMed
  102. Harikumar KG, Ball AM, Sexton PM, Miller LJ. Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization. Regul Pept. 2010 Sep 24; 164 (2-3):113-9 Epub 2010 June 10
    View PubMed
  103. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, Sexton PM. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol. 2010 Sep; 78(3):456-65. Epub 2010 Jun 14.
    View PubMed
  104. Chen Q, Pinon DI, Miller LJ, Dong M. Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity. J Biol Chem. 2010 Aug 6; 285 (32):24508-18 Epub 2010 June 07
    View PubMed
  105. Chen Q, Miller LJ, Dong M. Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor. Am J Physiol Endocrinol Metab. 2010 Jul; 299 (1):E62-8 Epub 2010 Apr 20
    View PubMed
  106. Dong M, Narang P, Pinon DI, Bordner AJ, Miller LJ. Refinement of the pharmacophore of an agonist ligand of the secretin receptor using conformationally constrained cyclic hexapeptides. Peptides. 2010 Jun; 31 (6):1094-8 Epub 2010 Mar 07
    View PubMed
  107. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010 Jun; 62(2):265-304. Epub 2010 Apr 14.
    View PubMed
  108. Pioszak AA, Harikumar KG, Parker NR, Miller LJ, Xu HE. Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation. J Biol Chem. 2010 Apr 16; 285(16):12435-44. Epub 2010 Feb 19.
    View PubMed
  109. Harikumar KG, Akgun E, Portoghese PS, Miller LJ. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization. J Med Chem. 2010 Apr 8; 53 (7):2836-42
    View PubMed
  110. Decker GA, Batheja MJ, Collins JM, Silva AC, Mekeel KL, Moss AA, Nguyen CC, Lake DF, Miller LJ. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y). 2010 Apr; 6(4):246-54.
    View PubMed
  111. Korner M, Waser B, Reubi JC, Miller LJ. CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours. J Cell Mol Med. 2010 Apr; 14 (4):933-43 Epub 2009 July 20
    View PubMed
  112. Dong M, Lam PC, Pinon DI, Orry A, Sexton PM, Abagyan R, Miller LJ. Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment. J Biol Chem. 2010 Mar 26; 285 (13):9919-9931 Epub 2010 Jan 25
    View PubMed
  113. Cawston EE, Miller LJ. Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br J Pharmacol. 2010 Mar; 159 (5):1009-21 Epub 2009 Nov 18
    View PubMed
  114. Harikumar KG, Simms J, Christopoulos G, Sexton PM, Miller LJ. Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor. Biochemistry. 2009 Dec 15; 48 (49):11773-85
    View PubMed
  115. Chen Q, Pinon DI, Miller LJ, Dong M. Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem. 2009 Dec 4; 284 (49):34135-44 Epub 2009 Oct 08
    View PubMed
  116. Dong M, Miller LJ. Effects of pH and temperature on photoaffinity labeling of Family B G protein-coupled receptors. Regul Pept. 2009 Nov 27; 158 (1-3):110-5 Epub 2009 May 18
    View PubMed
  117. Dong M, Cox RF, Miller LJ. Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action. J Biol Chem. 2009 Aug 14; 284 (33):21839-21847 Epub 2009 May 15
    View PubMed
  118. Korner M, Miller LJ. Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol. 2009 Aug; 175(2):461-72. Epub 2009 Jul 02.
    View PubMed
  119. Gao F, Harikumar KG, Dong M, Lam PC, Sexton PM, Christopoulos A, Bordner A, Abagyan R, Miller LJ. Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. Mol Pharmacol. 2009 Aug; 76 (2):264-74 Epub 2009 May 08
    View PubMed
  120. Dong M, Lam PC, Pinon DI, Abagyan R, Miller LJ. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling. Biochemistry. 2009 Jun 16; 48 (23):5303-12
    View PubMed
  121. Akgun E, Korner M, Gao F, Harikumar KG, Waser B, Reubi JC, Portoghese PS, Miller LJ. Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem. 2009 Apr 9; 52 (7):2138-47
    View PubMed
  122. Zheng Y, Akgun E, Harikumar KG, Hopson J, Powers MD, Lunzer MM, Miller LJ, Portoghese PS. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. J Med Chem. 2009 Jan 22; 52(2):247-58.
    View PubMed
  123. Simms J, Hall NE, Lam PH, Miller LJ, Christopoulos A, Abagyan R, Sexton PM. Homology modeling of GPCRs. Methods Mol Biol. 2009; 552:97-113.
    View PubMed
  124. Harikumar KG, Miller LJ. Application of fluorescence resonance energy transfer techniques to establish ligand-receptor orientation. Methods Mol Biol. 2009; 552:293-304
    View PubMed
  125. Harikumar KG, Miller LJ. Use of fluorescence indicators in receptor ligands. Methods Mol Biol. 2009; 552:279-91
    View PubMed
  126. Dong M, Pinon DI, Miller LJ. Exploration of the endogenous agonist mechanism for activation of secretin and VPAC1 receptors using synthetic glycosylated peptides. J Mol Neurosci. 2008 Nov; 36 (1-3):254-9 Epub 2008 Apr 12
    View PubMed
  127. Harikumar KG, Morfis MM, Sexton PM, Miller LJ. Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. J Mol Neurosci. 2008 Nov; 36 (1-3):279-85 Epub 2008 Apr 10
    View PubMed
  128. Harikumar KG, Happs RM, Miller LJ. Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. Biochim Biophys Acta. 2008 Nov; 1778 (11):2555-63 Epub 2008 July 17
    View PubMed
  129. Miller LJ. Informed development of drugs acting at family B G protein-coupled receptors. Ann N Y Acad Sci. 2008 Nov; 1144:203-9.
    View PubMed
  130. Harikumar KG, Miller LJ. Monitoring the state of cholecystokinin receptor oligomerization after ligand binding using decay of time-resolved fluorescence anisotropy. Ann N Y Acad Sci. 2008 Nov; 1144:21-7
    View PubMed
  131. Miller LJ. G protein-coupled receptor structures, molecular associations, and modes of regulation. Ann N Y Acad Sci. 2008 Nov; 1144:1-5
    View PubMed
  132. Harikumar KG, Gao F, Pinon DI, Miller LJ. Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor. Biochemistry. 2008 Sep 9; 47 (36):9574-81 Epub 2008 Aug 13
    View PubMed
  133. Wu SV, Harikumar KG, Burgess RJ, Reeve JR Jr, Miller LJ. Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation. Am J Physiol Gastrointest Liver Physiol. 2008 Sep; 295 (3):G641-7
    View PubMed
  134. Dong M, Lam PC, Pinon DI, Sexton PM, Abagyan R, Miller LJ. Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol. 2008 Aug; 74 (2):413-22 Epub 2008 May 08
    View PubMed
  135. Gao F, Sexton PM, Christopoulos A, Miller LJ. Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorg Med Chem Lett. 2008 Aug 1; 18 (15):4401-4 Epub 2008 June 20
    View PubMed
  136. Kumar M, Reeve JR Jr, Hu W, Miller LJ, Keire DA. The micelle-associated 3D structures of Boc-Y(SO3)-Nle-G-W-Nle-D-2-phenylethylester (JMV-180) and CCK-8(s) share conformational elements of a calculated CCK1 receptor-bound model. J Med Chem. 2008 Jul 10; 51(13):3742-54. Epub 2008 Jun 10.
    View PubMed
  137. Miller LJ, Gao F. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther. 2008 Jul; 119 (1):83-95 Epub 2008 May 11
    View PubMed
  138. Dong M, Gao F, Pinon DI, Miller LJ. Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol. 2008 Jun; 22 (6):1489-99 Epub 2008 Mar 27
    View PubMed
  139. Korner MU, Hayes GM, Carrigan PE, Rehmann R, Miller LJ, Reubi JC. Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue. Mod Pathol. 2008 Apr; 21(4):387-95. Epub 2008 Jan 25.
    View PubMed
  140. Bingham JL, Carrigan PE, Miller LJ, Srinivasan S. Extent and diversity of human alternative splicing established by complementary database annotation and microarray analysis. OMICS. 2008 Mar; 12(1):83-92.
    View PubMed
  141. Tokunaga H, Matsuura B, Dong M, Miller LJ, Ueda T, Furukawa S, Hiasa Y, Onji M. Mutational analysis of predicted intracellular loop domains of human motilin receptor. Am J Physiol Gastrointest Liver Physiol. 2008 Feb; 294(2):G460-6. Epub 2007 Nov 21.
    View PubMed
  142. Carrigan PE, Hentz JG, Gordon G, Morgan JL, Raimondo M, Anbar AD, Miller LJ. Distinctive heavy metal composition of pancreatic juice in patients with pancreatic carcinoma. Cancer Epidemiol Biomarkers Prev. 2007 Dec; 16(12):2656-63.
    View PubMed
  143. Harikumar KG, Lam PC, Dong M, Sexton PM, Abagyan R, Miller LJ. Fluorescence resonance energy transfer analysis of secretin docking to its receptor: mapping distances between residues distributed throughout the ligand pharmacophore and distinct receptor residues. J Biol Chem. 2007 Nov 9; 282 (45):32834-43 Epub 2007 Sept 07
    View PubMed
  144. Harikumar KG, Pinon DI, Miller LJ. Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor. J Biol Chem. 2007 Oct 19; 282 (42):30363-72 Epub 2007 Aug 28
    View PubMed
  145. Hayes GM, Carrigan PE, Dong M, Reubi JC, Miller LJ. A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma. Gastroenterology. 2007 Sep; 133 (3):853-61 Epub 2007 June 20
    View PubMed
  146. Dong M, Lam PC, Gao F, Hosohata K, Pinon DI, Sexton PM, Abagyan R, Miller LJ. Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor. Mol Pharmacol. 2007 Aug; 72(2):280-90. Epub 2007 May 02.
    View PubMed
  147. Lisenbee CS, Harikumar KG, Miller LJ. Mapping the architecture of secretin receptors with intramolecular fluorescence resonance energy transfer using acousto-optic tunable filter-based spectral imaging. Mol Endocrinol. 2007 Aug; 21 (8):1997-2008 Epub 2007 May 15
    View PubMed
  148. Miller LJ, Dong M, Harikumar KG, Gao F. Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor. Biochem Soc Trans. 2007 Aug; 35(Pt 4):709-12.
    View PubMed
  149. Dong M, Ding XQ, Thomas SE, Gao F, Lam PC, Abagyan R, Miller LJ. Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction. Biochemistry. 2007 Apr 17; 46 (15):4522-31 Epub 2007 Mar 24
    View PubMed
  150. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 2007 Mar 1; 67 (5):2072-80
    View PubMed
  151. Decker GA, Leighton JA, Harrison ME, Nguyen CC, Das A, Pasha SF, Moss AA, Miller LJ. New technology, new complications: Pancreatitis complicating double-balloon enteroscopy. Gastroenterol. Hepatol. 2007; 3(12):920-2.
  152. Miller LJ, Dong M, Harikumar KG, Lisenbee CS. Biochemical and cell biological mechanisms of cholecystokinin receptor regulation. Curr Top Med Chem. 2007; 7 (12):1166-72
    View PubMed
  153. Harikumar KG, Dong M, Cheng Z, Pinon DI, Lybrand TP, Miller LJ. Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function. Biochemistry. 2006 Dec 12; 45 (49):14706-16
    View PubMed
  154. Korner M, Hayes GM, Rehmann R, Zimmermann A, Scholz A, Wiedenmann B, Miller LJ, Reubi JC. Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. J Hepatol. 2006 Dec; 45(6):825-35. Epub 2006 Jul 28.
    View PubMed
  155. Harikumar KG, Pinon DI, Miller LJ. Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors. J Biol Chem. 2006 Sep 15; 281 (37):27072-80 Epub 2006 July 20
    View PubMed
  156. Lisenbee CS, Miller LJ. Secretin receptor oligomers form intracellularly during maturation through receptor core domains. Biochemistry. 2006 Jul 11; 45 (27):8216-26
    View PubMed
  157. Dong M, Miller LJ. Use of photoaffinity labeling to understand the molecular basis of ligand binding to the secretin receptor. Ann N Y Acad Sci. 2006 Jul; 1070:248-64.
    View PubMed
  158. Dong M, Miller LJ. Molecular approximation between residue 10 of secretin and its receptor demonstrated by photoaffinity labeling. Ann N Y Acad Sci. 2006 Jul; 1070:243-7.
    View PubMed
  159. Dong M, Pinon DI, Asmann YW, Miller LJ. Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors. Mol Pharmacol. 2006 Jul; 70(1):206-13. Epub 2006 Mar 10.
    View PubMed
  160. Dong M, Hosohata K, Pinon DI, Muthukumaraswamy N, Miller LJ. Differential spatial approximation between secretin and its receptor residues in active and inactive conformations demonstrated by photoaffinity labeling. Mol Endocrinol. 2006 Jul; 20(7):1688-98. Epub 2006 Mar 02.
    View PubMed
  161. Matsuura B, Dong M, Naik S, Miller LJ, Onji M. Differential contributions of motilin receptor extracellular domains for peptide and non-peptidyl agonist binding and activity. J Biol Chem. 2006 May 5; 281(18):12390-6. Epub 2006 Mar 10.
    View PubMed
  162. Harikumar KG, Pinon DI, Miller LJ. Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor. Biosci Rep. 2006 Apr; 26(2):89-100.
    View PubMed
  163. Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 2006 Apr 1; 66 (7):3819-27
    View PubMed
  164. Takeshita E, Matsuura B, Dong M, Miller LJ, Matsui H, Onji M. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol. 2006 Mar; 41(3):223-30.
    View PubMed
  165. Hadac EM, Dawson ES, Darrow JW, Sugg EE, Lybrand TP, Miller LJ. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. J Med Chem. 2006 Feb 9; 49 (3):850-63
    View PubMed
  166. Harikumar KG, Hosohata K, Pinon DI, Miller LJ. Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor. J Biol Chem. 2006 Feb 3; 281 (5):2543-50 Epub 2005 Nov 30
    View PubMed
  167. Harikumar KG, Morfis MM, Lisenbee CS, Sexton PM, Miller LJ. Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol Pharmacol. 2006 Jan; 69 (1):363-73 Epub 2005 Oct 21
    View PubMed
  168. Korner M, Hayes GM, Rehmann R, Zimmermann A, Friess H, Miller LJ, Reubi JC. Secretin receptors in normal and diseased human pancreas - Marked reduction of receptor binding in ductal neoplasia. Am J Pathol. 2005 Oct; 167(4):959-68.
    View PubMed
  169. Pham V, Dong MQ, Wade JD, Miller LJ, Morton CJ, Ng H, Parker MW, Sexton PM. Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling. J Biol Chem. 2005 Aug 5; 280(31):28610-22.
    View PubMed
  170. Dong M, Pinon DI, Miller LJ. Insights into the structure and molecular basis of ligand docking to the G protein-coupled secretin receptor using charge-modified amino-terminal agonist probes. Mol Endocrinol. 2005 Jul; 19 (7):1821-36 Epub 2005 Feb 24
    View PubMed
  171. Dong M, Hadac EM, Pinon DI, Miller LJ. Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations. Mol Pharmacol. 2005 Jun; 67(6):1892-900. Epub 2005 Mar 17.
    View PubMed
  172. Matsuura B, Dong M, Coulie B, Pinon DI, Miller LJ. Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog. Journal of Pharmacology & Experimental Therapeutics. 2005 Jun; 313(3):1101-8.
    View PubMed
  173. Harikumar KG, Miller LJ. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor. J Biol Chem. 2005 May 13; 280 (19):18631-5 Epub 2005 Mar 09
    View PubMed
  174. Cheng ZJ, Harikumar KG, Ding WQ, Holicky EL, Miller LJ. Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer. Cancer Lett. 2005 May 10; 222(1):95-105.
    View PubMed
  175. Dong M, Liu G, Pinon DI, Miller LJ. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. Biochemistry. 2005 May 3; 44(17):6693-700.
    View PubMed
  176. Lisenbee CS, Dong M, Miller LJ. Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor. J Biol Chem. 2005 Apr 1; 280 (13):12330-8 Epub 2005 Jan 21
    View PubMed
  177. Harikumar KG, Puri V, Singh RD, Hanada K, Pagano RE, Miller LJ. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem. 2005 Jan 21; 280 (3):2176-85 Epub 2004 Nov 10
    View PubMed
  178. Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy. J Biol Chem. 2005 Jan 14; 280 (2):1044-50 Epub 2004 Nov 01
    View PubMed
  179. Asmann YW, Dong M, Miller LJ. Functional characterization and purification of the secretin receptor expressed in baculovirus-infected insect cells. Regul Pept. 2004 Dec 15; 123(1-3):217-23.
    View PubMed
  180. Arlander SJ, Dong M, Ding XQ, Pinon DI, Miller LJ. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist. Mol Pharmacol. 2004 Sep; 66(3):545-52.
    View PubMed
  181. Dong M, Pinon DI, Cox RF, Miller LJ. Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor. J Biol Chem. 2004 Jul 23; 279 (30):31177-82 Epub 2004 May 20
    View PubMed
  182. Conti AM, Brimijoin S, Brimijoin S, Miller LJ, Windebank AJ. Suppression of neurite outgrowth by high-dose nerve growth factor is independent of functional p75NTR receptors. Neurobiol Dis. 2004 Feb; 15 (1):106-14
    View PubMed
  183. Dong M, Li Z, Pinon DI, Lybrand TP, Miller LJ. Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor. J Biol Chem. 2004 Jan 23; 279 (4):2894-903 Epub 2003 Oct 30
    View PubMed
  184. Dong M, Pinon DI, Cox RF, Miller LJ. Importance of the amino terminus in secretin family G protein-coupled receptors. Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor. J Biol Chem. 2004 Jan 9; 279 (2):1167-75 Epub 2003 Oct 28
    View PubMed
  185. Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer. Mol Pharmacol. 2004 Jan; 65(1):28-35.
    View PubMed
  186. Cheng ZJ, Harikumar KG, Holicky EL, Miller LJ. Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth. J Biol Chem. 2003 Dec 26; 278 (52):52972-9 Epub 2003 Oct 08
    View PubMed
  187. Dong M, Li Z, Zang M, Pinon DI, Lybrand TP, Miller LJ. Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor. Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor. J Biol Chem. 2003 Nov 28; 278 (48):48300-12 Epub 2003 Sept 18
    View PubMed
  188. Fernandez-Zapico ME, Mladek A, Ellenrieder V, Folch-Puy E, Miller L, Urrutia R. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. EMBO J. 2003 Sep 15; 22 (18):4748-58
    View PubMed
  189. Zang M, Dong M, Pinon DI, Ding XQ, Hadac EM, Li Z, Lybrand TP, Miller LJ. Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor. Mol Pharmacol. 2003 May; 63 (5):993-1001
    View PubMed
  190. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003 Mar; 55(1):167-94.
    View PubMed
  191. Ding WQ, Dong M, Ninova D, Holicky EL, Stegall MD, Miller LJ. Forskolin suppresses insulin gene transcription in islet beta-cells through a protein kinase A-independent pathway. Cell Signal. 2003 Jan; 15 (1):27-35
    View PubMed
  192. Ding XQ, Dolu V, Hadac EM, Schuetz M, Miller LJ. Disulfide bond structure and accessibility of cysteines in the ectodomain of the cholecystokinin receptor: specific mono-reactive receptor constructs examine charge-sensitivity of loop regions. Recept Channels. 2003; 9 (2):83-91
    View PubMed
  193. Miller LJ, Lybrand TP. Molecular basis of agonist binding to the type A cholecystokinin receptor. Pharmacol Toxicol. 2002 Dec; 91 (6):282-5
    View PubMed
  194. Harikumar KG, Miller LJ. Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor. Pharmacol Toxicol. 2002 Dec; 91 (6):286-9
    View PubMed
  195. Dawson ES, Henne RM, Miller LJ, Lybrand TP. Moleular models for cholecystokinin-A receptor. Pharmacology & Toxicology. 2002 Dec; 91(6):290-6.
    View PubMed
  196. Dong M, Pinon DI, Miller LJ. Development of a biologically active secretin analogue incorporating a radioiodinatable photolabile p-(4-hydroxybenzoyl)phenylalanine in position 10. Regul Pept. 2002 Nov 15; 109 (1-3):181-7
    View PubMed
  197. Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ, Raimondo M, Clain JE, Norton IA, Pearson RK, Petersen BT, Wiersema MJ, Farnell MB, Sarr MG. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002 Nov; 123 (5):1500-7
    View PubMed
  198. Dong MQ, Zang MW, Pinon DI, Li ZJ, Lybrand TP, Miller LJ. Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. Mol Endocrinol. 2002 Nov; 16(11):2490-501.
    View PubMed
  199. Ding WQ, Cheng ZJ, McElhiney J, Kuntz SM, Miller LJ. Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res. 2002 Sep 15; 62(18):5223-9.
    View PubMed
  200. Harikumar KG, Pinon DI, Wessels WS, Prendergast FG, Miller LJ. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor. J Biol Chem. 2002 May 24; 277 (21):18552-60 Epub 2002 Mar 13
    View PubMed
  201. Ding XQ, Pinon DI, Furse KE, Lybrand TP, Miller LJ. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol Pharmacol. 2002 May; 61 (5):1041-52
    View PubMed
  202. Matsuura B, Dong M, Miller LJ. Differential determinants for peptide and non-peptidyl ligand binding to the motilin receptor. Critical role of second extracellular loop for peptide binding and action. J Biol Chem. 2002 Mar 22; 277 (12):9834-9 Epub 2002 Jan 07
    View PubMed
  203. Ding WQ, Kuntz S, Bohmig M, Wiedenmann B, Miller LJ. Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Gastroenterology. 2002 Feb; 122 (2):500-11
    View PubMed
  204. Ding WQ, Kuntz SM, Miller LJ. A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. Cancer Res. 2002 Feb 01; 62: (3)947-52.
    View PubMed
  205. Dong M, Miller LJ. Molecular pharmacology of the secretin receptor. Recept Channels. 2002; 8 (3-4):189-200
    View PubMed
  206. Ding WQ, Dong M, Ninova D, Holicky EL, Stegall MD, Miller LJ. Forskolin surpresses insulin gene transcription in islet beta cells through a protein kinase A-independent pathway. Cellular Signaling. 2002; 15:27-35.
  207. Ding WQ, Miller LJ. Signaling from novel splice variants of hormone receptors in cancer. Int J Gastrointest Cancer. 2002; 31 (1-3):31-9
    View PubMed
  208. Cheng ZJ, Miller LJ. Agonist-dependent dissociation of oligomeric complexes of G protein-coupled cholecystokinin receptors demonstrated in living cells using bioluminescence resonance energy transfer. J Biol Chem. 2001 Dec 21; 276 (51):48040-7 Epub 2001 Oct 22
    View PubMed
  209. Shin DM, Luo X, Wilkie TM, Miller LJ, Peck AB, Humphreys-Beher MG, Muallem S. Polarized expression of G protein-coupled receptors and an all-or-none discharge of Ca2+ pools at initiation sites of [Ca2+]i waves in polarized exocrine cells. J Biol Chem. 2001 Nov 23; 276(47):44146-56. Epub 2001 Sep 11
    View PubMed
  210. Ding WQ, Holicky E, Miller LJ. Glucose and forskolin regulate IAPP gene expression through different signal transduction pathways. Am J Physiol Endocrinol Metab. 2001 Nov; 281 (5):E938-45
    View PubMed
  211. Coulie B, Matsuura B, Dong M, Hadac EM, Pinon DI, Feighner SD, Howard AD, Miller LJ. Identification of peptide ligand-binding domains within the human motilin receptor using photoaffinity labeling. J Biol Chem. 2001 Sep 21; 276 (38):35518-22 Epub 2001 July 18
    View PubMed
  212. Ding XQ, Ding WQ, Miller LJ. Receptor biology and signal transduction. Curr Opin Gastroenterol. 2001 Sep; 17 (5):410-5
    View PubMed
  213. Nardone G, Holicky EL, Uhl JR, Sabatino L, Staibano S, Rocco A, Colantuoni V, Manzo BA, Romano M, Budillon G, Cockerill FR, Miller LJ. In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection. Infect Immun. 2001 Sep; 69(9):5857-63.
    View PubMed
  214. Roettger BF, Hellen EH, Burghardt TP, Miller LJ. Multiple ligand and cell-dependent states of lateral mobility of plasmalemmal G protein-coupled cholecystokinin receptors. Journal of Fluorescence. 2001 Sep; 11(3):237-46.
  215. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001 Sep; 121 (3):640-5
    View PubMed
  216. Ding XQ, Miller LJ. Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies. Peptides. 2001 Aug; 22 (8):1223-8
    View PubMed
  217. Holicky EL, Hadac EM, Ding XQ, Miller LJ. Molecular characterization and organ distribution of type A and B cholecystokinin receptors in cynomolgus monkey. Am J Physiol Gastrointest Liver Physiol. 2001 Aug; 281 (2):G507-14
    View PubMed
  218. Jiang SW, Dong M, Trujillo MA, Miller LJ, Eberhardt NL. DNA binding of TEA/ATTS domain factors is regulated by protein kinase C phosphorylation in human choriocarcinoma cells. J Biol Chem. 2001 Jun 29; 276 (26):23464-70 Epub 2001 Apr 19
    View PubMed
  219. Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, Miller LJ. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe. J Biol Chem. 2001 Feb 9; 276 (6):4236-44 Epub 2000 Oct 24
    View PubMed
  220. Tietz PS, Hadac EM, Miller LJ, LaRusso NF. Upregulation of secretin receptors on cholangiocytes after bile duct ligation. Regul Pept. 2001 Feb 2; 97 (1):1-6
    View PubMed
  221. Miller LJ, Ding XQ. Insights into the molecular basis of ligand binding by the cholecystokinin receptor. Pancreatology. 2001; 1(4):336-42.
    View PubMed
  222. Rao RV, Holicky EL, Kuntz SM, Miller LJ. CCK receptor phosphorylation exposes regulatory domains affecting phosphorylation and receptor trafficking. Am J Physiol Cell Physiol. 2000 Dec; 279 (6):C1986-92
    View PubMed
  223. Ding XQ, Rao RV, Kuntz SM, Holicky EL, Miller LJ. Impaired resensitization and recycling of the cholecystokinin receptor by co-expression of its second intracellular loop. Mol Pharmacol. 2000 Dec; 58 (6):1424-33
    View PubMed
  224. Miller LJ, Coulie B. Characterization of the motilin receptor, a member of a new receptor family. Dig Liver Dis. 2000 Dec; 32 Suppl 3:S223-4
    View PubMed
  225. Asmann YW, Dong M, Ganguli S, Hadac EM, Miller LJ. Structural insights into the amino-terminus of the secretin receptor: I. Status of cysteine and cystine residues. Mol Pharmacol. 2000 Nov; 58 (5):911-9
    View PubMed
  226. Park CG, Ganguli SC, Pinon DI, Hadac EM, Miller LJ. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation. Journal of Pharmacology & Experimental Therapeutics. 2000 Nov; 295(2):682-8.
    View PubMed
  227. Dong M, Asmann YW, Zang M, Pinon DI, Miller LJ. Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor. J Biol Chem. 2000 Aug 25; 275 (34):26032-9
    View PubMed
  228. Dong M, Wang Y, Wang Y, Miller LJ. Dual contacts between peptide agonist ligands and the secretin receptor directly established by photoaffinity labeling. Ann N Y Acad Sci. 2000; 921:381-6
    View PubMed
  229. Pang RT, Ng SS, Cheng CH, Holtmann MH, Miller LJ, Chow BK. Role of N-linked glycosylation on the function and expression of the human secretin receptor. Endocrinology. 1999 Nov; 140(11):5102-11.
    View PubMed
  230. Sternini C, Wong H, Pham T, De Giorgio R, Miller LJ, Kuntz SM, Reeve JR, Walsh JH, Raybould HE. Expression of cholecystokinin A receptors in neurons innervating the rat stomach and intestine. Gastroenterology. 1999 Nov; 117(5):1136-46.
    View PubMed
  231. Dong M, Wang Y, Hadac EM, Wang Y, Pinon DI, Holicky E, Miller LJ. Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J Biol Chem. 1999 Jul 2; 274 (27):19161-7
    View PubMed
  232. Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely. J Med Chem. 1999 Jun 17; 42(12):2105-11.
    View PubMed
  233. Miller LJ. Advances in molecular genetics for the pancreatologist. Curr Gastroenterol Rep. 1999 Apr; 1 (2):132-3
    View PubMed
  234. Roettger BF, Pinon DI, Burghardt TP, Miller LJ. Regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist. Am J Physiol. 1999 Mar; 276 (3):C539-47
    View PubMed
  235. Roettger BF, Pinon DI, Burghardt TP, Miller LJ. Regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist. Am J Physiol Cell Physiol. 1999 Mar 1; 276 (3):C539-C547
    View PubMed
  236. Dong M, Ding XQ, Pinon DI, Hadac EM, Oda RP, Landers JP, Miller LJ. Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis. J Biol Chem. 1999 Feb 19; 274 (8):4778-85
    View PubMed
  237. Dong M, Wang Y, Pinon DI, Wang Y, Hadac EM, Miller LJ. Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling. J Biol Chem. 1999 Jan 8; 274 (2):903-9
    View PubMed
  238. Ulrich CD 2nd, Wood P, Hadac EM, Kopras E, Whitcomb DC, Miller LJ. Cellular distribution of secretin receptor expression in rat pancreas. Am J Physiol. 1998 Dec; 275(6 Pt 1):G1437-44.
    View PubMed
  239. Ulrich CD 2nd, Wood P, Hadac EM, Kopras E, Whitcomb DC, Miller LJ. Cellular distribution of secretin receptor expression in rat pancreas. Am J Physiol Gastrointest Liver Physiol. 1998 Dec 1; 275 (6):G1437-G1444
    View PubMed
  240. Darrow JW, Hadac EM, Miller LJ, Sugg EE. Structurally similar small molecule photoaffinity CCK-a agonists and antagonists as novel tools for directly probing 7TM receptor-ligand interactions. Bioorg Med Chem Lett. 1998 Nov 17; 8(22):3127-32.
    View PubMed
  241. Urrutia R, Miller LJ. Novel membrane-to-nucleus pathways in the regulation of pancreatic acinar cell function. Curr Opin Gastroenterol. 1998 Sep; 14(5):369-375.
  242. Ganguli SC, Park CG, Holtmann MH, Hadac EM, Kenakin TP, Miller LJ. Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. J Pharmacol Exp Ther. 1998 Aug; 286(2):593-8.
    View PubMed
  243. Go WY, Holicky EL, Hadac EM, Rao RV, Miller LJ. Identification of a domain in the carboxy terminus of CCK receptor that affects its intracellular trafficking. Am J Physiol. 1998 Jul; 275 (1):G56-62
    View PubMed
  244. Go WY, Holicky EL, Hadac EM, Rao RV, Miller LJ. Identification of a domain in the carboxy terminus of CCK receptor that affects its intracellular trafficking. Am J Physiol Gastrointest Liver Physiol. 1998 Jul 1; 275 (1):G56-G62
    View PubMed
  245. Hadac EM, Pinon DI, Ji Z, Holicky EL, Henne RM, Lybrand TP, Miller LJ. Direct identification of a second distinct site of contact between cholecystokinin and its receptor. J Biol Chem. 1998 May 22; 273 (21):12988-93
    View PubMed
  246. Smeets RL, Rao RV, van Emst-de Vries SE, De Pont JJ, Miller LJ, Willems PH. Reduced cholecystokinin receptor phosphorylation and restored signalling in protein kinase C down-regulated rat pancreatic acinar cells. Pflugers Arch. 1998 Feb; 435(3):422-8.
    View PubMed
  247. Ulrich CD 2nd, Holtmann M, Miller LJ. Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. Gastroenterology. 1998 Feb; 114 (2):382-97
    View PubMed
  248. Marlowe KJ, Farshori P, Torgerson RR, Anderson KL, Miller LJ, McNiven MA. Changes in kinesin distribution and phosphorylation occur during regulated secretion in pancreatic acinar cells. Eur J Cell Biol. 1998 Feb; 75 (2):140-52
    View PubMed
  249. Urrutia R, Urrutia R, Miller LJ, DiMagno EP. 1996 Comfort Symposium on Pancreatic Carcinogenesis. Pancreas. 1998 Jan; 16 (1):1-5
    View PubMed
  250. Urrutia R, Miller LJ, Dimagno EP. 1999 Cell signaling and transcription regulation in acinar epithelial cells. Curr Opin Gastroenterol. 1998; 16(1):1-5.
  251. Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, Miller LJ. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J Biol Chem. 1997 Sep 26; 272 (39):24393-401
    View PubMed
  252. Ghanekar D, Hadac EM, Holicky EL, Miller LJ. Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor. Journal of Pharmacology & Experimental Therapeutics. 1997 Sep; 282(3):1206-12.
    View PubMed
  253. Dong MQ, Oda RP, Strausbauch MA, Wettstein PJ, Landers JP, Miller LJ. Hydrophobic peptide mapping of clinically relevant heptahelical membrane proteins by capillary electrophoresis. Electrophoresis. 1997 Sep; 18(10):1767-1774.
    View PubMed
  254. Rao RV, Hadac EM, Roettger BF, Miller LJ. Cholecystokinin-induced desensitization, receptor phosphorylation, and internalization in the CHP212 neuroblastoma cell line. J Neurochem. 1997 Jun; 68 (6):2356-62
    View PubMed
  255. Go WY, Roettger BF, Holicky EL, Hadac EM, Miller LJ. Quantitative dynamic multicompartmental analysis of cholecystokinin receptor movement in a living cell using dual fluorophores and reconstruction of confocal images. Anal Biochem. 1997 May 1; 247(2):210-5.
    View PubMed
  256. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, Miller LJ. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol. 1997 Mar; 51(3):357-62.
    View PubMed
  257. Fischer de Toledo C, Roettger BF, Morys-Wortmann C, Schmidt WE, Miller LJ. Cellular handling of unoccupied and agonist-stimulated cholecystokinin receptor determined by immunolocalization. Am J Physiol. 1997 Mar; 272 (3 Pt 1):G488-97
    View PubMed
  258. Rao RV, Roettger BF, Hadac EM, Miller LJ. Roles of cholecystokinin receptor phosphorylation in agonist-stimulated desensitization of pancreatic acinar cells and receptor-bearing Chinese hamster ovary cholecystokinin receptor cells. Mol Pharmacol. 1997 Feb; 51 (2):185-92
    View PubMed
  259. Alpini G, Ulrich C, Roberts S, Phillips JO, Ueno Y, Podila PV, Colegio O, LeSage GD, Miller LJ, LaRusso NF. Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am J Physiol. 1997 Feb; 272 (2 Pt 1):G289-97
    View PubMed
  260. Holtmann MH, Hadac EM, Ulrich CD, Miller LJ. Molecular basis and species specificity of high affinity binding of vasoactive intestinal polypeptide by the rat secretin receptor. J Pharmacol Exp Ther. 1996 Nov; 279(2):555-60.
    View PubMed
  261. Holtmann MH, Roettger BF, Pinon DI, Miller LJ. Role of receptor phosphorylation in desensitization and internalization of the secretin receptor. J Biol Chem. 1996 Sep 20; 271 (38):23566-71
    View PubMed
  262. Ji Z, Pinon DI, Miller LJ. Development of magnetic beads for rapid and efficient metal-chelate affinity purifications. Anal Biochem. 1996 Sep 5; 240(2):197-201.
    View PubMed
  263. Hadac EM, Ghanekar DV, Holicky EL, Pinon DI, Dougherty RW, Miller LJ. Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation. Pancreas. 1996 Aug; 13 (2):130-9
    View PubMed
  264. Holtmann MH, Ganguli S, Hadac EM, Dolu V, Miller LJ. Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J Biol Chem. 1996 Jun 21; 271 (25):14944-9
    View PubMed
  265. Ozcelebi F, Rao RV, Holicky E, Madden BJ, McCormick DJ, Miller LJ. Phosphorylation of cholecystokinin receptors expressed on Chinese hamster ovary cells. Similarities and differences relative to native pancreatic acinar cell receptors. J Biol Chem. 1996 Feb 16; 271 (7):3750-5
    View PubMed
  266. Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW Jr, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J Med Chem. 1996 Jan 19; 39(2):562-9.
    View PubMed
  267. Katz M, Carangelo R, Miller LJ, Gorelick F. Effect of ethanol on cholecystokinin-stimulated zymogen conversion in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol. 1996 Jan; 33(1):G 171-G 175.
  268. Belov L, Akhter J, Meher-Homji V, Nicholson S, Miller LJ, Morris DL. Monoclonal antibody 2C1 does not recognise the CCK-B (gastrin) receptor. Surg Res Commun. 1996; 18:183-95.
  269. Nardone G, Ferber IA, Miller LJ. The integrity of the cholecystokinin receptor gene in gallbladder disease and obesity. Hepatology. 1995 Dec; 22(6):1751-3.
    View PubMed
  270. Tietz PS, Holman RT, Miller LJ, LaRusso NF. Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry. 1995 Nov 28; 34 (47):15436-43
    View PubMed
  271. Ozcelebi F, Holtmann MH, Rentsch RU, Rao R, Miller LJ. Agonist-stimulated phosphorylation of the carboxyl-terminal tail of the secretin receptor. Mol Pharmacol. 1995 Nov; 48(5):818-24.
    View PubMed
  272. Miller LJ, Holicky EL, Ulrich CD, Wieben ED. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology. 1995 Oct; 109 (4):1375-80
    View PubMed
  273. Roettger BF, Rentsch RU, Hadac EM, Hellen EH, Burghardt TP, Miller LJ. Insulation of a G protein-coupled receptor on the plasmalemmal surface of the pancreatic acinar cell. J Cell Biol. 1995 Aug; 130 (3):579-90
    View PubMed
  274. Holtmann MH, Hadac EM, Miller LJ. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J Biol Chem. 1995 Jun 16; 270 (24):14394-8
    View PubMed
  275. Roettger BF, Rentsch RU, Pinon D, Holicky E, Hadac E, Larkin JM, Miller LJ. Dual pathways of internalization of the cholecystokinin receptor. J Cell Biol. 1995 Mar; 128 (6):1029-41
    View PubMed
  276. Ozcelebi F, Miller LJ. Phosphopeptide mapping of cholecystokinin receptors on agonist-stimulated native pancreatic acinar cells. J Biol Chem. 1995 Feb 17; 270 (7):3435-41
    View PubMed
  277. Sugg EE, Kimery MJ, Ding JM, Kenakin DC, Miller LJ, Queen KL, Rimele TJ. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A- 71623). J Med Chem. 1995 Jan 6; 38(1):207-11.
    View PubMed
  278. Lutz MP, Pinon DI, Miller LJ. A nonradioactive fluorescent gel-shift assay for the analysis of protein phosphatase and kinase activities toward protein-specific peptide substrates. Anal Biochem. 1994 Aug 1; 220(2):268-74.
    View PubMed
  279. Miller LJ, Hadac EM, Powers SP. Preparation of radiolabeled photolabile probes of high specific radioactivity for affinity labeling. Anal Biochem. 1994 Aug 1; 220(2):434-5.
    View PubMed
  280. Lutz MP, Pinon DI, Miller LJ. Characterization of protein serine/threonine phosphatases in rat pancreas and development of an endogenous substrate-specific phosphatase assay. Pancreas. 1994 Jul; 9 (4):418-24
    View PubMed
  281. Gaisano HY, Miller LJ. Low concentrations of protein kinase C-activating agonists suppress cholecystokinin-OPE-evoked Ca2+ mobilization in rat pancreatic acini. Pancreas. 1994 Jul; 9(4):450-3.
    View PubMed
  282. Gaisano HY, Miller LJ, Foskett JK. Suppression of Ca2+ oscillations induced by cholecystokinin (CCK) and its analog OPE in rat pancreatic acinar cells by low-level protein kinase C activation without transition of the CCK receptor from a high- to low-affinity state. Pflugers Arch. 1994 Jul; 427(5-6):455-62.
    View PubMed
  283. Alpini G, Ulrich CD 2nd, Phillips JO, Pham LD, Miller LJ, LaRusso NF. Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation. Am J Physiol. 1994 May; 266 (5 Pt 1):G922-8
    View PubMed
  284. Zhu Z, Lutz M, Gates LK, Miller LJ. Mechanisms of heterologous agonist-stimulated phosphorylation of cholecystokinin receptor. Am J Physiol. 1994 Apr; 266 (4 Pt 1):C904-10
    View PubMed
  285. Ulrich CD 2nd, Pinon DI, Hadac EM, Holicky EL, Chang-Miller A, Gates LK, Miller LJ. Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. Gastroenterology. 1993 Nov; 105 (5):1534-43
    View PubMed
  286. Lutz MP, Pinon DI, Gates LK, Shenolikar S, Miller LJ. Control of cholecystokinin receptor dephosphorylation in pancreatic acinar cells. J Biol Chem. 1993 Jun 5; 268 (16):12136-42
    View PubMed
  287. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G, Miller LJ. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun. 1993 May 28; 193(1):204-11.
    View PubMed
  288. Lutz MP, Sutor SL, Abraham RT, Miller LJ. A role for cholecystokinin-stimulated protein tyrosine phosphorylation in regulated secretion by the pancreatic acinar cell. J Biol Chem. 1993 May 25; 268 (15):11119-24
    View PubMed
  289. Gates LK, Ulrich CD, Miller LJ. Multiple kinases phosphorylate the pancreatic cholecystokinin receptor in an agonist-dependent manner. Am J Physiol. 1993 May; 264 (5 Pt 1):G840-7
    View PubMed
  290. Marino CR, Leach SD, Schaefer JF, Miller LJ, Gorelick FS. Characterization of cAMP-dependent protein kinase activation by CCK in rat pancreas. FEBS Lett. 1993 Jan 18; 316(1):48-52.
    View PubMed
  291. Miller LJ. Cell-surface receptors and pancreatic acinar cell physiology. Curr Opin Gastroenterol. 1993; 9:732-739.
  292. Lutz MP, Miller LJ. Cholecystokinin receptors: radioligand binding and affinity labeling. Methods in Neurosciences. 1993; 11:170-185.
  293. Miller LJ. The biochemical characterization of the native pancreatic cholecystokinin receptor using affinity labeling approaches. Yale J Biol Med. 1992 Sep-Oct; 65 (5):441-8; discussion 465-9
    View PubMed
  294. Gaisano HY, Miller LJ. Complex role of protein kinase C in mediating the supramaximal inhibition of pancreatic secretion observed with cholecystokinin. Biochem Biophys Res Commun. 1992 Aug 31; 187 (1):498-506
    View PubMed
  295. Farley DR, van Heerden JA, Grant CS, Miller LJ, Ilstrup DM. The Zollinger-Ellison syndrome. A collective surgical experience. Ann Surg. 1992 Jun; 215 (6):561-9; discussion 569-70
    View PubMed
  296. Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF Jr, Beinborn M. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A. 1992 Apr 15; 89(8):3605-9.
    View PubMed
  297. Miller LJ, Hadac EM, Gates LK, Gaisano HY. Binding of a phenethyl ester analogue of cholecystokinin to the solubilized pancreatic cholecystokinin receptor: use in ligand-affinity chromatography. Biochem Biophys Res Commun. 1992 Mar 16; 183 (2):396-404
    View PubMed
  298. Miller LJ. Pancreatic acinar cell physiology and function. Curr Opin Gastroenterol. 1992; 8:801-807.
  299. Farley DR, Van Heerden JA, Grant CS, Miller LJ, Ilstrup DM. The Zollinger-Ellison syndrome. Trans South Surg Assoc. 1991 Dec; 103:165-174.
  300. Kamath PS, Gaisano HY, Phillips SF, Miller LJ, Charboneau JW, Brown ML, Zinsmeister AR. Abnormal gallbladder motility in irritable bowel syndrome: evidence for target-organ defect. Am J Physiol. 1991 Jun; 260 (6 Pt 1):G815-9
    View PubMed
  301. Klueppelberg UG, Gates LK, Gorelick FS, Miller LJ. Agonist-regulated phosphorylation of the pancreatic cholecystokinin receptor. J Biol Chem. 1991 Feb 5; 266 (4):2403-8
    View PubMed
  302. Molero X, Miller LJ. The gall bladder cholecystokinin receptor exists in two guanine nucleotide-binding protein-regulated affinity states. Mol Pharmacol. 1991 Feb; 39(2):150-6.
    View PubMed
  303. Powers SP, Foo I, Pinon D, Klueppelberg UG, Hedstrom JF, Miller LJ. Use of photoaffinity probes containing poly(ethylene glycol) spacers for topographical mapping of the cholecystokinin receptor complex. Biochemistry. 1991 Jan 22; 30 (3):676-82
    View PubMed
  304. Otterness DM, Powers SP, Miller LJ, Weinshilboum RM. 3'-Phosphoadenosine-5'-phosphosulfate: photoaffinity ligand for sulfotransferase enzymes. Mol Pharmacol. 1991 Jan; 39(1):34-41.
    View PubMed
  305. Lennon VA, Sas DF, Busk MF, Scheithauer B, Malagelada JR, Camilleri M, Miller LJ. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology. 1991 Jan; 100 (1):137-42
    View PubMed
  306. Kost LJ, Gores GJ, Sayles JM, Miller LJ, Lemasters JJ, Herman B, LaRusso NF. Lack of metabolic effects of cholecystokinin on hepatocytes. Hepatology. 1990 Aug; 12 (2):301-5
    View PubMed
  307. Tanaka M, Sarr MG, Miller LJ, Malagelada JR. Changes in tone of canine gallbladder measured by an electronic pneumatic barostat. Am J Physiol. 1990 Aug; 259 (2 Pt 1):G314-20
    View PubMed
  308. Klueppelberg UG, Molero X, Barrett RW, Miller LJ. Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells. Mol Pharmacol. 1990 Aug; 38(2):159-63.
    View PubMed
  309. Hunter EB, Powers SP, Kost LJ, Pinon DI, Miller LJ, LaRusso NF. Physicochemical determinants in hepatic extraction of small peptides. Hepatology. 1990 Jul; 12 (1):76-82
    View PubMed
  310. Schjoldager B, Molero X, Miller LJ. Gallbladder CCK receptors: species differences in glycosylation of similar protein cores. Regul Pept. 1990 May 21; 28 (3):265-72
    View PubMed
  311. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, MacCarty RL, Ciociola A. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci. 1990 Apr; 35 (4):477-80
    View PubMed
  312. Klueppelberg UG, Powers SP, Miller LJ. The efficiency of covalent labeling of the pancreatic cholecystokinin receptor using a battery of cross-linkable and photolabile probes. Receptor. 1990; 1:1-11.
    View PubMed
  313. Otterness DM, Powers SP, Miller LJ, Weinshilboum RM. Human liver thermostable phenol sulfotransferase: photoaffinity labeling with 2-iodo-4-azidophenol. Mol Pharmacol. 1989 Dec; 36(6):856-65.
    View PubMed
  314. Duong LT, Hadac EM, Miller LJ, Vlasuk GP. Purification and characterization of the rat pancreatic cholecystokinin receptor. J Biol Chem. 1989 Oct 25; 264(30):17990-6.
    View PubMed
  315. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, Ciociola A. Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci. 1989 Oct; 34 (10):1511-5
    View PubMed
  316. Klueppelberg UG, Powers SP, Miller LJ. Protease peptide mapping of affinity-labeled rat pancreatic cholecystokinin-binding proteins. Biochemistry. 1989 Aug 22; 28 (17):7124-9
    View PubMed
  317. Sas DF, Lundy JK, Miller LJ. Culture of human neoplastic gastrointestinal smooth muscle cells. In Vitro Cell Dev Biol. 1989 Aug; 25 (8):730-6
    View PubMed
  318. Gores GJ, Kost LJ, Miller LJ, LaRusso NF. Processing of cholecystokinin by isolated liver cells. Am J Physiol. 1989 Aug; 257 (2 Pt 1):G242-8
    View PubMed
  319. Pearson RK, Hadac EM, Miller LJ. Structural analysis of a distinct subtype of CCK receptor on human gastric smooth muscle tumors. Am J Physiol. 1989 Jun; 256 (6 Pt 1):G1005-10
    View PubMed
  320. Klueppelberg UG, Gaisano HY, Powers SP, Miller LJ. Use of a nitrotryptophan-containing peptide for photoaffinity labeling the pancreatic cholecystokinin receptor. Biochemistry. 1989 Apr 18; 28 (8):3463-8
    View PubMed
  321. Schjoldager B, Molero X, Miller LJ. Functional and biochemical characterization of the human gallbladder muscularis cholecystokinin receptor. Gastroenterology. 1989 Apr; 96 (4):1119-25
    View PubMed
  322. Gaisano HY, Klueppelberg UG, Pinon DI, Pfenning MA, Powers SP, Miller LJ. Novel tool for the study of cholecystokinin-stimulated pancreatic enzyme secretion. J Clin Invest. 1989 Jan; 83 (1):321-5
    View PubMed
  323. Schjoldager B, Powers SP, Miller LJ. Affinity labeling the bovine gallbladder cholecystokinin receptor using a battery of probes. Am J Physiol. 1988 Nov; 255 (5 Pt 1):G579-86
    View PubMed
  324. Sas D, Miller LJ. Culture behavior of healthy bovine gallbladder muscularis smooth muscle cells. Am J Physiol. 1988 Nov; 255 (5 Pt 1):G653-9
    View PubMed
  325. Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility of the small intestine in irritable bowel syndrome. Gut. 1988 Sep; 29 (9):1236-43
    View PubMed
  326. Powers SP, Pinon DI, Miller LJ. Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. Int J Pept Protein Res. 1988 May; 31 (5):429-34
    View PubMed
  327. Powers SP, Fourmy D, Gaisano H, Miller LJ. Intrinsic photoaffinity labeling probes for cholecystokinin (CCK)-gastrin family receptors. D-Tyr-Gly-[Nle28,31,pNO2-Phe33)CCK-26-33). J Biol Chem. 1988 Apr 15; 263 (11):5295-300
    View PubMed
  328. Schjoldager B, Shaw MJ, Powers SP, Schmalz PF, Szurszewski J, Miller LJ. Bovine gallbladder muscularis: source of a myogenic receptor for cholecystokinin. Am J Physiol. 1988 Mar; 254 (3 Pt 1):G294-9
    View PubMed
  329. Miller LJ, Powers SP. Biochemical characterization of the pancreatic cholecystokinin receptor: a possible marker of cell differentiation and development. Scand J Gastroenterol Suppl. 1988; 151:104-7.
    View PubMed
  330. Kellow JE, Miller LJ, Phillips SF, Zinsmeister AR, Charboneau JW. Altered sensitivity of the gallbladder to cholecystokinin octapeptide in irritable bowel syndrome. Am J Physiol. 1987 Nov; 253 (5 Pt 1):G650-5
    View PubMed
  331. Shaw MJ, Hadac EM, Miller LJ. Preparation of enriched plasma membranes from bovine gallbladder muscularis for characterization of cholecystokinin receptors. J Biol Chem. 1987 Oct 15; 262 (29):14313-8
    View PubMed
  332. Pearson RK, Miller LJ, Hadac EM, Powers SP. Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. J Biol Chem. 1987 Oct 5; 262 (28):13850-6
    View PubMed
  333. Pearson RK, Powers SP, Hadac EM, Gaisano H, Miller LJ. Establishment of a new short, protease-resistant, affinity labeling reagent for the cholecystokinin receptor. Biochem Biophys Res Commun. 1987 Aug 31; 147(1):346-53.
    View PubMed
  334. Kellow JE, Miller LJ, Phillips SF, Haddad AC, Zinsmeister AR, Charboneau JW. Sensitivities of human jejunum, ileum, proximal colon, and gallbladder to cholecystokinin octapeptide. Am J Physiol. 1987 Mar; 252(3 Pt 1):G345-56.
    View PubMed
  335. Pearson RK, Miller LJ. Affinity labeling of a novel cholecystokinin-binding protein in rat pancreatic plasmalemma using new short probes for the receptor. J Biol Chem. 1987 Jan 15; 262(2):869-76.
    View PubMed
  336. Pearson RK, Miller LJ, Powers SP, Hadac EM. Biochemical characterization of the pancreatic cholecystokinin receptor using monofunctional photoactivatable probes. Pancreas. 1987; 2(1):79-84.
    View PubMed
  337. van Heerden JA, Smith SL, Miller LJ. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type I. Surgery. 1986 Dec; 100(6):971-7.
    View PubMed
  338. Pearson RK, Hadac EM, Miller LJ. Preparation and characterization of a new cholecystokinin receptor probe that can be oxidatively radioiodinated. Gastroenterology. 1986 Jun; 90(6):1985-91.
    View PubMed
  339. Miller LJ, Bouska JB, Go VL. Extraction of cholecystokinin peptides from biological fluids using octadecylsilane-packed cartridges. J Chromatogr. 1986 May 28; 378(1):77-84.
    View PubMed
  340. Gores GJ, Miller LJ, LaRusso NF. Hepatic processing of cholecystokinin peptides. II. Cellular metabolism, transport, and biliary excretion. Am J Physiol. 1986 Mar; 250(3 Pt 1):G350-6.
    View PubMed
  341. Gores GJ, LaRusso NF, Miller LJ. Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol. 1986 Mar; 250(3 Pt 1):G344-9.
    View PubMed
  342. Gaisano HY, Reilly W, Go VL, Olivero D, Miller LJ. Large molecular forms of cholecystokinin circulating in humans. Pancreas. 1986; 1(2):148-53.
    View PubMed
  343. Tietz PS, Thistle JL, Miller LJ, LaRusso NF. Development and validation of a method for measuring the glycine and taurine conjugates of bile acids in bile by high-performance liquid chromatography. J Chromatogr. 1984 Dec 12; 336(2):249-57.
    View PubMed
  344. Miller LJ. Characterization of cholecystokinin receptors on human gastric smooth muscle tumors. Am J Physiol. 1984 Oct; 247(4 Pt 1):G402-10.
    View PubMed
  345. Miller LJ, Jardine I, Weissman E, Go VL, Speicher D. Characterization of cholecystokinin from the human brain. J Neurochem. 1984 Sep; 43(3):835-40.
    View PubMed
  346. Miller LJ, Bartholomew LG, Dozois RR, Dahlin DC. Adenocarcinoma of the rectum arising in a hamartomatous polyp in a patient with Peutz-Jeghers syndrome. Dig Dis Sci. 1983 Nov; 28(11):1047-51.
    View PubMed
  347. Miller LJ, Reilly WM, Rosenzweig SA, Jamieson JD, Go VLW. A soluble interaction between dibutyryl cyclic guanosine 3':5'-monophosphate and cholecystokinin: a possible mechanism for the inhibition of cholecystokinin activity. Gastroenterology. 1983 Jun; 84:1505-1511.
    View PubMed
  348. Miller LJ. Small intestinal manifestations of diabetes mellitus. Yale Journal of Biology & Medicine. 1983 May-Jun; 56(3):189-93.
    View PubMed
  349. McCullough AJ, Miller LJ, Service FJ, Go VL. Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric inhibitory polypeptide. J Clin Endocrinol Metab. 1983 Feb; 56(2):234-41.
    View PubMed
  350. Go VL, Miller LJ. The role of gastrointestinal hormones in the control of postprandial and interdigestive gastrointestinal function. Scand J Gastroenterol Suppl. 1983; 82:135-42.
    View PubMed
  351. Rosenzweig SA, Miller LJ, Jamieson JD. Identification and localization of cholecystokinin binding sites on rat pancreatic plasma membranes and acinar cells: a biochemical and morphological study. J Cell Biol. 1983; 96:1288-1297.
    View PubMed
  352. Miller LJ, Reilly WM, Rosenweig SA, Jamieson JD, Go VLW. The mechanism by which dibutyryl cyclic GMP antagonizes the action of cholecystokinin. Gastroenterology. 1983; 84:1637-1639.
    View PubMed
  353. Owyang C, Miller LJ, Malagelada JR, Go VL. Nutrient and bowel segment dependency of human intestinal control of gastric secretion. Am J Physiol. 1982 Nov; 243(5):G372-6.
    View PubMed
  354. Kelly DG, Miller LJ, Malagelada JR, Huizenga KA, Markowitz H. Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology. 1982 Sep; 83(3):581-9.
    View PubMed
  355. Owyang C, Miller LJ, DiMagno EP, Mitchell JC 3rd, Go VL. Pancreatic exocrine function in severe human chronic renal failure. Gut. 1982 May; 23(5):357-61.
    View PubMed
  356. Rees WD, Malagelada JR, Miller LJ, Go VL. Human interdigestive and postprandial gastrointestinal motor and gastrointestinal hormone patterns. Dig Dis Sci. 1982 Apr; 27(4):321-9.
    View PubMed
  357. Miller LJ, Malagelada JR, Taylor WF, Go VL. Intestinal control of human postprandial gastric function: the role of components of jejunoileal chyme in regulating gastric secretion and gastric emptying. Gastroenterology. 1981 Apr; 80(4):763-9.
    View PubMed
  358. Miller LJ, Rosenzweig SA, Jamieson JD. Preparation and characterization of a probe for the cholecystokinin octapeptide receptor, N-alpha-125-I-desaminotyrosyl) CCK-8, and its interactions with pancreatic acini. J Biol Chem. 1981; 256:12417-12423.
    View PubMed
  359. Miller LJ, Malagelada JR, Longstreth GF, Go VL. Dysfunctions of the stomach with gastric ulceration. Dig Dis Sci. 1980 Nov; 25(11):857-64.
    View PubMed
  360. McGill DB, Miller LJ, Carney JA, Phillips SF, Go VLW, Schutt AJ. Hormonal diarrhea due to pancreatic tumor. Gastroenterology. 1980 Sep; 79:571-582.
  361. Miller LJ, Owyang C, Malagelada JR, Gorman CA, Go VL. Gastric, pancreatic, and biliary responses to meals in hyperthyroidism. Gut. 1980 Aug; 21(8):695-700.
    View PubMed
  362. Miller LJ, Resseguie LJ, Taylor WF, Malagelada JR. Cholecystectomy and gastric ulcer--an etiologic relationship? Mayo Clin Proc. 1980 Apr; 55(4):255-7.
    View PubMed
  363. Rees WD, Miller LJ, Malagelada JR. Dyspepsia, antral motor dysfunction, and gastric stasis of solids. Gastroenterology. 1980 Feb; 78(2):360-5.
    View PubMed
  364. Krawisz BR, Miller LJ, DiMagno EP, Go VL. In the absence of nutrients, pancreatic-biliary secretions in the jejunum do not exert feedback control of human pancreatic or gastric function. Journal of Laboratory & Clinical Medicine. 1980 Jan; 95(1):13-8.
    View PubMed
  365. Owyang C, Miller LJ, DiMagno EP, Brennan LA Jr, Go VL. Gastrointestinal hormone profile in renal insufficiency. Mayo Clin Proc. 1979 Dec; 54(12):769-73.
    View PubMed
  366. Owyang C, Miller LJ, Lie JT, Fleming CR. Takayasu's arteritis in Crohn's disease. Gastroenterology. 1979 Apr; 76:825-828.
    View PubMed
  367. Miller LJ, Clain JE, Malagelada JR, Go VL. Control of human postprandial pancreatic exocrine secretion: a function of the gastroduodenal region. Dig Dis Sci. 1979 Feb; 24(2):150-4.
    View PubMed
  368. Miller LJ, Gorman CA, Go VL. Gut-thyroid interrelationships. Gastroenterology. 1978 Nov; 75(5):901-11.
    View PubMed
  369. Miller LJ, Malagelada JR, Go VL. Intestinal nutrient influence on the enteroinsular axis. J Clin Endocrinol Metab. 1978 Nov; 47(5):1009-14.
    View PubMed
  370. Miller LJ, Malagelada JR, Go VL. Postprandial duodenal function in man. Gut. 1978 Aug; 19(8):699-736.
    View PubMed
  371. Miller LJ, Thistle JL, Payne WS, Gaffey TA, O'Duffy JD. Crohn's disease involving the esophagus and colon. Case report. Mayo Clin Proc. 1977 Jan; 52(1):35-8.
    View PubMed
  372. Gordon SJ, Miller LJ, Haeffner LJ, Kinsey MD, Kowlessar OD. Abnormal intestinal bile acid distribution in azotemic man: a possible role in the pathogenesis of uremic diarrhea. Gut. 1976; 17:58-67.
    View PubMed
  373. Miller LJ, Gordon SJ, Haeffner LJ, Saukkonen JJ, Kinsey MD, Kowlessar OD. Bile acid abnormalities in uremic man. Gastroenterology. 1974; 66:746.
PST-20220057